AKT1 and endometrial cancer: Analysis of PI3K/AKT/mTOR pathway signalling revealed that taxane-resistant endometrial cancer cells had increased pathway activity: taxane-resistant AN3CA cells displayed 6-fold higher phosphorylated-S6 and 3-fold elevation in phosphorylated-AKT (Fig. 4c, d).